Deals in Depth: August 2010
Disclosed pre-commercial potential deal values in pharma alliances were on the low side in August - topping the list at only $80 million was Biogen Idec's license to Knopp's Phase II ALS candidate. Life Technologies gained more DNA sequencing tools through its $375 million buy of Ion Torrent Systems in a transaction that also includes $350 million in earn-outs. Pharma financing was up 20% from July, while device company fund-raising was down by more than half.
You may also be interested in...
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.
At-home nail and hair care and e-commerce were bright spots in a numbing second quarter for Revlon, which was hit hard by mass retail and salon channel closures at a time of ongoing transformation.
Agency has created a centralized team to help review divisions with virtual advisory committee preparations and is trying to notify sponsors earlier in the review process about the need for a panel; sponsors cite importance of having a back channel of communications so team members can communicate with each other while an AdComm is underway.